Originating from the Ophthalmology Department of the Pseudomanchukuo Xinjing Municipal Special Hospital established in 1936, the center is currently led by Professor Su Guanfang, who serves as a standing committee member of the Chinese Medical Association Ophthalmology Branch. The Ophthalmology Diagnosis and Treatment Center is an advanced domestic and first-class medical, teaching, research, and blindness prevention and treatment center in Northeast China. It is designated as a National Clinical Key Specialty Construction Project Unit, the Jilin Provincial Branch of the National Clinical Research Center for Eye and ENT Diseases, a National Training Base for Key Faculty of Standardized Residency Training, a National Drug Clinical Trial Institution for Ophthalmology, a Jilin Provincial Key Discipline, and the host unit of the Jilin Provincial Medical Association Ophthalmology Branch. Additionally, it serves as the Jilin Provincial Ophthalmology Quality Control Center, Jilin Provincial Eye Disease Prevention and Treatment Center, Jilin Provincial Key Laboratory of Ophthalmology, Jilin Provincial Engineering Laboratory of Ophthalmology, and the Jilin Provincial Office for Blindness Prevention. In the latest Science and Technology Evaluation Metrics (STEM) ranking of Chinese hospitals, it ranks 18th nationwide.

The center comprises nine subspecialties: vitreoretinal diseases, glaucoma, cataract, orbital diseases and oculoplastics, strabismus and pediatric ophthalmology, ocular surface diseases and oculoplastic aesthetics, medical ophthalmology, optometry, and corneal refractive surgery. It currently employs 230 medical, nursing, and technical staff, including 30 senior title holders, 28 associate senior title holders, 75 doctoral degree holders, 11 doctoral supervisors, and 41 master's supervisors. The center has 314 open beds, an annual outpatient volume of over 300,000 visits, and handles more than 20,000 inpatient admissions and surgeries annually. It was among the first in China to perform minimally invasive vitreoretinal surgery, endoscopic orbital minimally invasive surgery, micro-incision phacoemulsification for cataract surgery, glaucoma aqueous drainage device implantation, complex strabismus surgery, femtosecond laser small incision lenticule extraction (SMILE), and anti-VEGF intravitreal injections for neovascular diseases.